Evidence-based guidelines for cardiovascular disease prevention in women

L Mosca, LJ Appel, EJ Benjamin, K Berra… - Circulation, 2004 - Am Heart Assoc
In the wake of the reports of the Women's Health Initiative and the Heart and
Estrogen/Progestin Replacement Study (HERS), which unexpectedly showed that …

2017 cardiovascular and stroke endpoint definitions for clinical trials

KA Hicks, KW Mahaffey, R Mehran, SE Nissen… - Circulation, 2018 - Am Heart Assoc
This publication describes uniform definitions for cardiovascular and stroke outcomes
developed by the Standardized Data Collection for Cardiovascular Trials Initiative and the …

AHA/ACCF Scientific statement on the evaluation of syncope: from the American heart association councils on clinical cardiology, cardiovascular nursing …

SA Strickberger, DW Benson, I Biaggioni, DJ Callans… - Circulation, 2006 - Am Heart Assoc
Conclusions… 324 Syncope, a transient loss of consciousness, is a common clinical
problem. The most common causes of syncope are cardiovascular in origin and are …

[HTML][HTML] Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct

RG Nogueira, AP Jadhav, DC Haussen… - … England Journal of …, 2018 - Mass Medical Soc
Background The effect of endovascular thrombectomy that is performed more than 6 hours
after the onset of ischemic stroke is uncertain. Patients with a clinical deficit that is …

[HTML][HTML] Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis

MI Chimowitz, MJ Lynn, H Howlett-Smith… - … England Journal of …, 2005 - Mass Medical Soc
Background Atherosclerotic intracranial arterial stenosis is an important cause of stroke.
Warfarin is commonly used in preference to aspirin for this disorder, but these therapies …

Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis

SE Kasner, MI Chimowitz, MJ Lynn, H Howlett-Smith… - Circulation, 2006 - Am Heart Assoc
Background—Antithrombotic therapy for intracranial arterial stenosis was recently evaluated
in the Warfarin versus Aspirin for Symptomatic Intracranial Disease (WASID) trial. A …

Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience

IL Katzan, AJ Furlan, LE Lloyd, JI Frank, DL Harper… - Jama, 2000 - jamanetwork.com
ContextLittle is known regarding outcomes after intravenous tissue-type plasminogen
activator (IV tPA) therapy for acute ischemic stroke outside a trial setting. ObjectiveTo assess …

The warfarin-aspirin symptomatic intracranial disease study

MI Chimowitz, J Kokkinos, J Strong, MB Brown… - Neurology, 1995 - AAN Enterprises
We conducted a retrospective, multicenter study to compare the efficacy of warfarin with
aspirin for the prevention of major vascular events (ischemic stroke, myocardial infarction, or …

Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial

CS Kase, AJ Furlan, LR Wechsler, RT Higashida… - Neurology, 2001 - AAN Enterprises
Objective: To analyze the frequency, clinical characteristics, and predictors of symptomatic
intracerebral hemorrhage (ICH) after intraarterial (IA) thrombolysis with recombinant pro …

Cooling for acute ischemic brain damage (COOL AID) An open pilot study of induced hypothermia in acute ischemic stroke

DW Krieger, MA De Georgia, A Abou-Chebl… - Stroke, 2001 - Am Heart Assoc
Background and Purpose—Hypothermia is effective in improving outcome in experimental
models of brain infarction. We studied the feasibility and safety of hypothermia in patients …